Hyloris Pharmaceuticals launches its IPO

Advertisement

Prospectus

The English language version of the Prospectus was approved by the Belgian Financial Services and Markets Authority (the "FSMA") on 16 June 2020, which approval should not be understood as an endorsement by the FSMA of the Company or the quality of the Offered Shares.

Hyloris Pharmaceuticals SA (“Hyloris Pharmaceuticals” or “Hyloris” or the (“Company”), an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals, intends to raise new funds through an Initial Public Offering (“IPO”) with admission of all of its shares on the regulated market of Euronext Brussels.

Hyloris, an early-stage innovative specialty pharmaceutical company 

Hyloris is focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. The Company develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim of addressing the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system.

Hyloris’ development strategy focuses on the Food & Drug Administration’s (“FDA”) 505(b)(2) regulatory pathway, which is specifically designed for  pharmaceuticals for which safety and efficacy of the molecule has been established. As compared to traditional New Drug Applications (NDAs) using the FDA’s 505(b)(1) regulatory pathway, the 505(b)(2) regulatory pathway can reduce the clinical burden required to bring a product to the market, significantly shorten the development timelines and reduce costs and risks.

To date, Hyloris’ operations have consisted primarily of the identification of  product candidates to build its pipeline and the formulation, testing and development of its existing portfolio. Today, Hyloris has established a diversified portfolio of 2 early-stage commercial products and 12 product candidates, the majority of which are in the early reformulation development stage. Hyloris’ portfolio has a particular focus on intravenous (“IV”) cardiovascular products, but it also contains other reformulation products and established markets products (high-barrier generics). The Company is continuously evaluating new development candidates to add to its portfolio, both internally and externally. 

For a detailed description of the risks that are specific to Hyloris, its industry, the shares and the offering, we refer to the prospectus which is available for prospective investors. 

Possibility to learn more about the company during retail webinar

The management of the company invites KBC Bank (Private Banking) customers to participate to a retail roadshow webinar, that will be given in Dutch, on 18 June 2020 at 18:00 (CET). There will be also a webinar organized in the French language. This will take place on 22 June 2020 at 18:00 (CET). Stijn Van Rompay (CEO) will be present during this online event. He will give more explanations about the company and the Initial Public Offering and answer your questions. Do you want to attend this retail roadshow webinar? Subscribe to the event here

Learn more about this IPO

For more information on Hyloris and the terms of the offering (including the prospectus and the product fiche), you can contact your KBC-branch or KBC Brussels-branch, KBC Live (+32 (0)78 152 153) or go to the KBC-website (www.kbc.be/hyloris).

For a detailed description of the risks that are specific to Hyloris, its industry, the shares and the offering, we refer to the prospectus, which is available for prospective investors at no cost at the registered office of Hyloris (Boulevard Gustave-Kleyer 17, 4000 Liège, Belgium). The prospectus is available free of charge in your KBC Bank branch or KBC Brussels branch, through KBC Live (+32 (0)78 152 153) or via www.kbc.be/hyloris. The English language version of the Prospectus was approved by the FSMA on 16 June 2020, which approval should not be understood as an endorsement by the FSMA of the Company or the quality of the Offered Shares. The prospectus is available in English and in French. A Dutch summary is also made available to prospective investors.

An investment in the Offered Shares involves substantial risks and uncertainties. Prospective investors should read the entire Prospectus, and, in particular, should see Part 2 - (Risk Factors) for a discussion of certain factors that should be considered in connection with an investment in the Offered Shares, including the risks relating to the fact that (i) Hyloris has a limited operating history and has not yet generated any substantial revenues. Hyloris has incurred operating losses, negative operating cash flows and an accumulated deficit since inception resulting in a negative equity at the date of the Prospectus and Hyloris may not be able to achieve or subsequently maintain profitability. Hyloris is executing its strategy in accordance with its business model, the viability of which not been demonstrated, (ii) Hyloris’ performance depends primarily on the success of its product candidates, a majority of which are in the early reformulation development stage and have not yet received FDA approval of the 505(b)(2) application or ANDA or the other approvals required before they may be commercially launched, (iii) even if Hyloris receives regulatory approval for any of its product candidates, it may be unable to launch the product successfully and the revenue that Hyloris generates from sales of such product, if any, may be limited, (iv) Hyloris has entered into arrangements with related parties and these arrangements present potential conflicts of interest, (v) certain of Hyloris’ directors and members of Hyloris’ executive management hold directorships or shareholdings in other pharmaceutical companies, which could create potential conflicts of interest, and (vi) after closing of the Offering, certain significant shareholders of the Issuer may have different interests from the Issuer and/or from the minority shareholders and may be able to control the Issuer, including the outcome of shareholder votes. Every decision to invest in the Offered Shares must be based on all information provided in the Prospectus. Potential investors must be able to bear the economic risk of an investment in the Offered Shares and to undergo a full or partial loss of their investment. All of these factors should be considered before investing in the Offered Shares. 

Register for the shares of Hyloris in the context of its IPO

As a retail investor you are able to subscribe at an offer price between €10.00 to €11.50 per share.

Registration for the shares of Hyloris in the context of this transaction as a retail investor is possible at Bolero from 17 June 2020 up to 16:00 (CEST) on 25 June 2020, subject to early closing.

There are no subscription charges relating to this Offering. No tax on stock exchange transactions is due on the subscription for newly issued Shares.

If you would like to subscribe to the shares of Hyloris in the context of its IPO on Euronext Brussels, please contact your KBC-Branch, KBC Brussels-branch or KBC Live (+32 (0)78 152 153) for more information. 

Documentation

We use cookies and similar technologies to make our website work better for you and ensure your online experience with us is more enjoyable and rewarding. We may also adapt our website to your needs and preferences. By continuing to use this website, you consent to our use of cookies. Learn more or reject cookies.